On Nov. 11, 2021, the University of Oxford began recruiting for a Phase I trial to test an Ebola vaccine in human volunteers. The study will assess the immune response and safety of the new vaccine against the Zaire and Sudan species of Ebola.

The vaccine is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine ﾖ or the Oxford-AstraZeneca vaccine.